NBP

$2.56-0.14 (-5.01%)

Market ClosedAs of Mar 20, 8:00 PM UTC

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.56
Potential Upside
5%
Whystock Fair Value$2.69
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$295.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-889.06%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
14.47

Recent News

The Fly
Feb 6, 2026

Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls

Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 5, 2026

Insider Spends US$5.1m Buying More Shares In NovaBridge Biosciences

NovaBridge Biosciences ( NASDAQ:NBP ) shareholders (or potential shareholders) will be happy to see that the Executive...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 8, 2026

Is There An Opportunity With NovaBridge Biosciences' (NASDAQ:NBP) 40% Undervaluation?

Key Insights The projected fair value for NovaBridge Biosciences is US$6.70 based on 2 Stage Free Cash Flow to Equity...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 19, 2025

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.